Section Arrow
AVIR.NASDAQ
- Atea Pharmaceuticals
Quotes are at least 15-min delayed:2025/04/15 14:49 EDT
Last
 2.815
-0.125 (-4.25%)
Day High 
2.95 
Prev. Close
2.94 
1-M High
3.29 
Volume 
269.48K 
Bid
2.81
Ask
2.82
Day Low
2.815 
Open
2.92 
1-M Low
2.6 
Market Cap 
251.44M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.79 
20-SMA 2.96 
50-SMA 3.01 
52-W High 4.145 
52-W Low 2.6 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.00/--
Enterprise Value
252.29M
Balance Sheet
Book Value Per Share
5.13
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Created with Highstock 5.0.121-min Chart10:0012:0014:002.82.852.92.953etnet.com.hk@copyright
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MURAMural Oncology plc2.4492+1.4192+137.79%-- 
SKYESkye Bioscience1.67+0.36+27.48%3.58PE
SPRBSpruce Biosciences0.1346-0.1798-57.19%-- 
VERVVerve Therapeutics5.051+0.931+22.60%-- 
DWTXDogwood Therapeutics Inc4.01+1.01+33.67%-- 
Quotes are at least 15-min delayed:2025/04/15 14:49 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.